Arrowhead Research is a publicly traded (NASDAQ: ARWR) pharmaceutical company that is a component of the NASDAQ Biotechnology Index. As of 2016[update], it has no marketed products. Products in development are RNA therapeutics acting through RNA interference mechanisms of action. The company focuses on treatments for Hepatitis B, and Carcinomare. The company has six products in its pipeline, in various stages of clinical development. In 2015, the company substantially expanded its intellectual property holdings through complete acquisition of the full RNAi research and development portfolio and assets from Novartis.